

*Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.*



廣州白雲山醫葯集團股份有限公司

**GUANGZHOU BAIYUNSHAN PHARMACEUTICAL HOLDINGS CO., LTD.**

*(a joint stock company with limited liability established in the People's Republic of China)*

(H Share Stock Code: 0874)

## **VOLUNTARY ANNOUNCEMENT**

This is a voluntary announcement made by Guangzhou Baiyunshan Pharmaceutical Holdings Company Limited (the “**Company**”).

According to “ Reply in relation to the filings of the first batch and the second batch high-tech enterprises in Guangdong Province in 2014” (Guo Ke Huo Zi [2015] No. 47)\* (《關於廣東省2014年第一、二批高新技術企業備案的覆函》(國科火字[2015]47號)) and its attachments published by the Office of the National High-tech Enterprises Recognition and Management Leading Group\* (全國高新技術企業認定管理工作領導小組辦公室) on the website of the Torch High Technology Industry Development Centre\* (火炬高技術產業開發中心) of the Ministry of Science and Technology of the People's Republic of China\* (中國科學技術部), a total of 12 enterprises comprising the Company and the enterprises under the Company were recognized as the first batch of the high-tech enterprises of the Guangdong Province in 2014, and the relevant high-tech enterprises certificates were issued on 10 October 2014. Details of which are set out below:

1. Company (Certificate No.: GR201444000590);
2. Guangzhou Baiyunshan Xing Qun Pharmaceutical Co., Ltd.\* (廣州白雲山星群(葯業)股份有限公司), a subsidiary of the Company which the Company owns 88.99% (Certificate No. GR201444000193);
3. Guangzhou Baiyunshan Han Fang Contemporary Pharmaceutical Co., Ltd.\* (廣州白雲山漢方現代葯業有限公司), a subsidiary of the Company which the Company owns 99.49% (Certificate No.: GR201444000631);
4. Guangzhou Baiyunshan Pan Gao Shou Pharmaceutical Co., Ltd.\* (廣州白雲山潘高壽葯業股份有限公司), a subsidiary of the Company which the Company owns 87.77% (Certificate No. GR201444000715);
5. Guangzhou Baiyunshan Zhong Yi Pharmaceutical Co., Ltd.\* (廣州白雲山中一葯業有限公司), a wholly-owned subsidiary of the Company (Certificate No.: GR201444000836);
6. Guangzhou Baiyunshan Tian Xin Pharmaceutical Co., Ltd.\* (廣州白雲山天心製葯股份有限公司), a subsidiary of the Company which the Company owns 82.49% (Certificate No. GR201444000895);

7. Guangzhou Baiyunshan Qi Xing Pharmaceutical Co., Ltd.\* (廣州白雲山奇星藥業有限公司), a subsidiary of the Company which the Company owns 75.00% (Certificate No.: GR201444001047);
8. Guangzhou Baiyunshan Chen Li Ji Pharmaceutical Factory Co., Ltd.\* (廣州白雲山陳李濟藥廠有限公司), a wholly-owned subsidiary of the Company (Certificate No.: GR201444001125);
9. Guangzhou Baiyunshan Ming Xing Pharmaceutical Co., Ltd.\* (廣州白雲山明興製藥有限公司), a wholly-owned subsidiary of the Company (Certificate No.: GR201444001349);
10. Guangzhou Baiyunshan Jing Xiu Tang Pharmaceutical Co., Ltd.\* (廣州白雲山敬修堂藥業股份有限公司), a subsidiary of the Company which the Company owns 88.40% (Certificate No.: GR201444001464);
11. Hutchison Whampoa Guangzhou Baiyunshan Chinese Medicine Co., Ltd.\* (廣州白雲山和記黃埔中藥有限公司), a joint venture which the Company owns 50% (Certificate No.: GR201444001291); and
12. Guangzhou Wang Lao Ji Pharmaceutical Co., Ltd.\* (廣州王老吉藥業股份有限公司), a company which the Company owns 48.05% (Certificate No.: GR201444000633).

Pursuant to the relevant rules and regulations, an enterprise shall be entitled to the relevant favourable policies for three consecutive years commencing from being recognized as high-tech enterprises, namely payment of corporate income tax at the rate of 15%.

With respect to the period from January to September 2014, the Company (not including any subsidiaries of the Company) paid corporate income tax at the rate of 25%. Assuming corporate income tax at the rate of 15%, the net profit under the consolidated statements of the Company attributable to the parent company for the period from January to September 2014 would increase by approximately RMB33.7482 million, representing a growth of 3.94%. The aforesaid figures have taken into account only the impact of the decline of the corporate income tax from the rate of 25% to 15% and have not taken into account other factors. The aforesaid figures have not been audited and are provided for reference only.

The Board of  
**Guangzhou Baiyunshan Pharmaceutical Holdings Company Limited**

Guangzhou, the PRC, 9 March 2015

*As at the date of this announcement, the board of directors comprises Mr. Li Chuyuan, Mr. Chen Mao, Ms. Liu Juyan, Ms. Cheng Ning, Mr. Ni Yidong, Mr. Wu Changhai and Mr. Wang Wenchu as executive directors, and Mr. Wong Lung Tak Patrick, Mr. Qiu Hongzhong, Mr. Fang Shuting and Mr. Chu Xiaoping as independent non-executive directors.*

\* For identification purpose only